ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Th17 cells and colitis
  • Th17 cells and Regulatory T cells
  • The Short Form Health Survey 36-item questionnaire (SF-36v2)
  • Therapeutic drug monitoring
  • therapeutic management
  • therapeutic targeting
  • therapeutic targeting and Cell Signaling
  • therapeutic targeting and tissue remodeling
  • therapeutic targeting and tolerance
  • therapeutic targeting and toll-like receptors
  • therapeutic targeting and treatment
  • therapeutic targeting and treatment options
  • therapeutic targeting and tumor necrosis factor (TNF)
  • therapeutic targeting and uric acid
  • therapeutic targeting and vaccines
  • therapy
  • therapy and fibrosis
  • therapy and immunoregulation
  • therapy and rheumatic disease
  • therapy and tocilizumab
  • therapy and toll-like receptors
  • therapy and treatment
  • therapy and tumor necrosis factor (TNF)
  • therapy and ultrasonography
  • therapy and uveitis
  • therapy and vaccination
  • therapy and vasculitis
  • Therapy, alternative
  • Therapy, complementary
  • thermal analysis
  • thermography and ultrasound
  • three-material decomposition
  • thrombocytopenia
  • thrombocytopenia and idiopathic thrombocytopenic purpura - ITP
  • thrombocytopenia and thrombosis
  • Thrombosis
  • thrombosis and Co-morbidities
  • thrombosis and connective tissue diseases
  • thrombosis and drug safety
  • thrombosis and international
  • thrombosis and Lupus
  • thrombosis and prognostic factors
  • thrombosis and race
  • thrombosis and risk factor
  • thrombosis and treatment
  • thrombosis and ultrasound
  • thrombosis and vasculitis
  • thrombosis and vessel vasculitis
  • thymectomy
  • thyroid
  • thyroid and anemia
  • thyroid cancer and incidence
  • thyroperoxidase and antinuclear antibodies (ANA)
  • tie
  • Tildrakizumab
  • time management and ultrasonography
  • Timed Function tests
  • tissue
  • Tissue Engineering
  • tissue growth factor (TGF)
  • tissue growth factor (TGF) and fibroblasts
  • tissue remodeling and tumor necrosis factor (TNF)
  • titer
  • TLR4
  • TLR7
  • TMJ
  • TNF-blocking Antibody
  • TNF-α blockers and Drug efficacy
  • TNFi and methotrexate (MTX)
  • TNFi and registries
  • TNFSF13 and migration inhibitory factor (MIF)
  • tobacco use
  • tobacco use and health disparities
  • tobacco use and rheumatoid arthritis (RA)
  • tobacco use and tofacitnib
  • tobacco use and total joint replacement
  • tobacco use and uveitis
  • tobacco use and vasculitis
  • Tocilizumab
  • tocilizumab and bioinformatics
  • tocilizumab and Biologics
  • tocilizumab and CLINICAL MANIFESTATIONS
  • tocilizumab and Disease Activity
  • tocilizumab and efficacy
  • tocilizumab and giant cell arteritis
  • tocilizumab and glucocorticoids
  • tocilizumab and large vessel vasculitis
  • tocilizumab and lipids
  • tocilizumab and methotrexate (MTX)
  • tocilizumab and prednisolone
  • tocilizumab and quality of life
  • tocilizumab and rheumatoid arthritis
  • tocilizumab and rituximab
  • tocilizumab and safety
  • tocilizumab and tofacitinib
  • tocilizumab and tofacitnib
  • tocilizumab and tolerance
  • tocilizumab and treatment
  • tocilizumab and treatment options
  • tocilizumab and tumor necrosis factor (TNF)
  • tocilizumab and ultrasound
  • tocilizumab and uveitis
  • tocilizumab and vaccines
  • tocilizumab and vasculitis
  • tocilizumab and viruses
  • Tofacitinib
  • tofacitinib and baricitinib
  • tofacitinib and cognitive dysfunction
  • tofacitinib and IL-17
  • tofacitinib and Janus kinase (JAK)
  • tofacitinib and lipids
  • tofacitinib and Reproductive Health
  • tofacitinib and salivary gland
  • tofacitinib and tofacitinib
  • tofacitinib and treatment
  • tofacitinib and treatment options
  • tofacitinib and tumor necrosis factor (TNF)
  • tofacitinib and ultrasound
  • Tofacitinib and vaccines
  • tofacitinib and viruses
  • tofacitinib and work
  • tofacitnib and tumor necrosis factor (TNF)
  • tofacitnib and work
  • tolerance
  • tolerance and toll-like receptors
  • tolerance and treatment
  • tolerance and vasculitis
  • tolerance and viruses
  • Toll Like receptors
  • toll-like receptors and innate immunity
  • toll-like receptors and interferons
  • toll-like receptors and transcriptional regulation
  • toll-like receptors and treatment
  • toll-like receptors and tumor necrosis factor (TNF)
  • toll-like receptors and vasculitis
  • toll-like receptors and viruses
  • tophaceous gout
  • tophaceous gout and tophi
  • Tophaceous gout and ultrasound
  • tophaceous gout and urate
  • tophaceous gout and uric acid
  • topoisomerase
  • Total Hip Arthroplasty
  • Total joint replacement
  • Total Knee Arthroplasty
  • Total Knee Arthroplasty (TKA)
  • Total Knee Arthroplasty (TKA) and anticoagulation
  • Total Knee Arthroplasty (TKA) and decision analysis
  • Total Knee Arthroplasty (TKA) and non-pharmacologic intervention
  • Total Knee Arthroplasty (TKA) and outcome measures
  • Total Knee Arthroplasty (TKA) and pain management
  • Total Knee Arthroplasty (TKA) and physical activity
  • Total Knee Arthroplasty (TKA) and psychosocial factors
  • Total Knee Arthroplasty (TKA) and rheumatoid arthritis (RA)
  • Tph and Synovial Immune Biology
  • trabecular bone score
  • tracer
  • TRACTISS
  • trainee
  • trainee and ultrasonography
  • trainee and ultrasound
  • transcription factor
  • transcription factor and gout
  • transcription factor and transcriptional regulation
  • transcription factor and transforming growth factor
  • transcription factor and tumor necrosis factor (TNF)
  • transcription factor and tumor suppressors
  • transcription factor and wounds
  • transcriptional regulation
  • transcriptional regulation and tumor necrosis factor (TNF)
  • transcriptome
  • Transcriptomic
  • transcriptomics
  • Transforming Growth Factor (TGF)
  • transforming growth factor and exosome
  • transforming growth factor and treatment
  • transforming growth factor and tyrosine kinase inhibition
  • transglutaminase-2 and myositis
  • transient elastography
  • Transition
  • Transition and doctor-patient relationship
  • Transition and health literacy
  • Transition and longitudinal studies
  • Transition and pediatric rheumatology
  • Transition and pediatrics
  • Transition and serologic tests
  • Transition and systemic lupus erythematosus (SLE)
  • Transition and young adults
  • transplant
  • transplantation
  • transplantation and complications
  • transplantation and renal disease
  • transplantation and treatment
  • transplantation and vasculitis
  • transplantation and vasculogenesis
  • Traps
  • Traps and canakinumab
  • Traps and genetic disorders
  • Traps and mitochondria
  • Trauma
  • First |
  • « Previous Page
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • [64]
  • 65
  • 66
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology